EXHIBIT 10.25 STANDARD FORM COMMERCIAL LEASE Steven D. Rosenberg as Trustee of the Fifth Street 1. PARTIES Realty Trust of 300 Bent Street, Cambridge, MA 02141 (fill in) LESSOR, which expression shall include his heirs, successors, and assigns where...Biogen Idec Inc • March 31st, 2005 • Biological products, (no disgnostic substances)
IDEC PHARMACEUTICALS CORPORATION (a Delaware corporation) 400,000 Shares of Common Stock INTERNATIONAL PURCHASE AGREEMENT Dated: November -o-, 2000 TABLE OF CONTENTS INTERNATIONAL PURCHASE AGREEMENTIdec Pharmaceuticals Corp / De • November 9th, 2000 • Biological products, (no disgnostic substances) • New York
EXHIBIT 99.2 Published CUSIP Number: [________________] CREDIT AGREEMENT Dated as of June 29, 2007Credit Agreement • July 2nd, 2007 • Biogen Idec Inc. • Biological products, (no disgnostic substances) • New York
EXHIBIT 99.1 LOAN AGREEMENT Dated as of June 28, 2007Loan Agreement • July 2nd, 2007 • Biogen Idec Inc. • Biological products, (no disgnostic substances) • New York
RECITALS:Lease • March 10th, 2004 • Biogen Idec Inc • Biological products, (no disgnostic substances)
CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.68 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT IS REQUESTED IS OMITTED AND IS NOTED WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS...Escrow Agreement • April 1st, 2002 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
Ex-10.44 SINGLE-TENANT FULLY-NET LEASE AGREEMENT (10996 TORREYANA ROAD) This Single-Tenant Fully-Net Lease Agreement (this "Lease") is entered into as of January 17, 2002, between 10996 TORREYANA ROAD, L.P., a California limited partnership...Lease Agreement • March 10th, 2004 • Biogen Idec Inc • Biological products, (no disgnostic substances) • California
TRUSTEEIdec Pharmaceuticals Corp / De • March 31st, 1999 • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT Dated as of August 28, 2015 amongCredit Agreement • September 1st, 2015 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT (“Agreement”) is entered into as of August 28, 2015, among BIOGEN INC., a Delaware corporation (the “Borrower”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), the L/C Issuers from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer.
EX-10.39 FIRST AMENDMENT TO LEASE This Agreement is entered into as of November 9, 1992, by and between TORREY SORRENTO INC., a California corporation (hereinafter called "Landlord"), and IDEC PHARMACEUTICALS CORPORATION, a California corporation...Lease • March 10th, 2004 • Biogen Idec Inc • Biological products, (no disgnostic substances)
BETWEENSupply Agreement • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
Amended and Restated Rights Agreement Dated as of July 26, 2001Rights Agreement • July 27th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • Delaware
ANDLicense Agreement • August 16th, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
AGREEMENT AND PLAN OF MERGER by and among REATA PHARMACEUTICALS, INC., BIOGEN INC. and RIVER ACQUISITION, INC. Dated as of July 28, 2023Agreement and Plan of Merger • July 31st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 28, 2023, by and among Biogen Inc., a Delaware corporation (“Parent”), River Acquisition, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
Biogen Idec Inc. Underwriting AgreementUnderwriting Agreement • March 4th, 2008 • Biogen Idec Inc. • Biological products, (no disgnostic substances)
Goldman, Sachs & Co. Merrill Lynch & Co. Merrill Lynch, Pierce, Fenner & Smith Incorporated As representatives of the several Underwriters named in Schedule I hereto,
Exhibit 10.35 FIFTH AMENDMENT TO AGREEMENT THIS FIFTH AMENDMENT TO AGREEMENT ("Fifth Amendment") is made and effective as of this 17th day of December, 2003, by and between MDS (CANADA) INC., MDS NORDION division, successor to MDS NORDION INC....To Agreement • March 10th, 2004 • Biogen Idec Inc • Biological products, (no disgnostic substances)
CREDIT AGREEMENT Dated as of January 28, 2020 among BIOGEN INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and the L/C Issuer, CITIBANK, N.A., DEUTSCHE BANK AG, NEW YORK BRANCH, GOLDMAN SACHS BANK USA, JPMORGAN...Credit Agreement • February 3rd, 2020 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.
IDEC PHARMACEUTICALS CORPORATION (a Delaware corporation) ISSUER $300,000,000 Liquid Yield Option Notes(TM) due 2019 (Zero Coupon -- Subordinated)Registration Rights Agreement • March 31st, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
BACKGROUNDAgreement • August 14th, 1997 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
1 2,000,000 SHARES IDEC PHARMACEUTICALS CORPORATION COMMON STOCK, $.001 PAR VALUE UNDERWRITING AGREEMENTIdec Pharmaceuticals Corp / De • February 24th, 1998 • Biological products, (no disgnostic substances) • New York
AMENDMENT TO CREDIT AGREEMENTCredit Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.
andRights Agreement • August 1st, 1997 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • Delaware
BETWEENCollaborative Research and License Agreement • March 30th, 2000 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.10 CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH...Purchase and Sale Agreement and Escrow Instructions • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
1 CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.11 CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED...License Agreement • August 14th, 2000 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
BIOGEN INC. and U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Debt Securities Dated as of September 15, 2015Biogen Inc. • September 16th, 2015 • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of September 15, 2015, by and between Biogen Inc., a Delaware corporation, as Issuer (the “Company”), and U.S. Bank National Association, a national association, as Trustee (the “Trustee”).
Biogen Inc.Biogen Inc. • April 30th, 2020 • Biological products, (no disgnostic substances) • New York
Biogen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman Sachs & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and each of the other Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the “Representatives”), the respective amounts set forth in Schedule I of $1,500,000,000 aggregate principal amount of the Company’s 2.250% Senior Notes due 2030 (the “2030 Notes”) and $1,500,000,000 aggregate principal amount of the Company’s 3.150% Senior Notes due 2050 (the “2050 Notes” and, together with the 2030 Notes, the “Securities”).
TERM LOAN CREDIT AGREEMENT Dated as of August 28, 2023 among BIOGEN INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as Administrative Agent and The Other Lenders Party Hereto JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., BANK OF CHINA, NEW YORK...Term Loan Credit Agreement • September 1st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
This TERM LOAN CREDIT AGREEMENT (this “Agreement”) is entered into as of August 28, 2023, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
BACKGROUNDCollaborative Development Agreement • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
COMMON STOCK (PAR VALUE $.0005 PER SHARE)Intersyndicate Agreement • November 9th, 2000 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
EXHIBIT 4.9 FIRST AMENDMENT TO THE RIGHTS AGREEMENT AND CERTIFICATION OF COMPLIANCE WITH SECTION 27 THEREOF Pursuant to Section 27 of the Rights Agreement (the "Agreement") dated as of July 22, 1997, between IDEC PHARMACEUTICALS CORPORATION, a...Rights Agreement • March 31st, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • July 31st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).
SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017Settlement and License Agreement • February 1st, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) dated as of the Agreement Date (as defined below), among each of the following Parties:
SEPARATION AGREEMENT by and between BIOGEN INC. and BIOVERATIV INC. Dated as of January 31, 2017Separation Agreement • February 2nd, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
This SEPARATION AGREEMENT (this “Agreement”), dated as of January 31, 2017, is entered into by and between Biogen Inc. (“Biogen”), a Delaware corporation, and Bioverativ Inc. (“Bioverativ”), a Delaware corporation and a wholly owned subsidiary of Biogen. “Party” or “Parties” means Biogen or Bioverativ, individually or collectively, as the case may be. Each capitalized term used and not elsewhere defined herein has the meaning set forth in Section 1.1.
RESTRICTED STOCK UNIT AWARD AGREEMENT GRANTED UNDERRestricted Stock Unit Award Agreement • April 24th, 2018 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
